Atrial Fibrillation Trial, Recruiting NCT06099730 Sponsor: Massachusetts General Hospital Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Atrial Fibrillation Trial, Recruiting

NCT06099730
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with atrial fibrillation (an irregular heartbeat) that comes and goes or is persistent, with at least one episode confirmed by a heart monitor or ECG recording within the past 24 months.
  • You are between 18 and 80 years old.
  • You are willing and able to sign a written consent form.
  • You are able and willing to attend all required appointments and follow-up visits before, during, and after the trial.

Who may not be able to join:

  • You have previously had surgery or a catheter-based procedure to treat atrial fibrillation.
  • A scan taken within 48 hours before the procedure found a blood clot in the upper left chamber of your heart.
  • You have severe, uncontrolled heart failure (the most serious level, where you experience symptoms even at rest).
  • You have a history of blood clotting or bleeding problems, or you cannot safely take blood-thinning medications.
  • You have a significant birth defect or other medical condition that the trial doctor believes would make participation unsafe (confirm with trial site).
  • You have an implanted pacemaker, defibrillator, or other metal heart device that could interfere with the treatment used in this trial.
  • You are pregnant, breastfeeding, or of childbearing age and planning to become pregnant during the trial.
  • Your life expectancy is less than 12 months.
  • You are currently taking part in another clinical trial involving a different device, treatment, or drug that could affect this study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
14 December 2023
Est. completion
1 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of early onset primary adverse events (PAEs); Freedom from documented atrial tachyarrhythmia episodes; Freedom from acute procedural failure

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov